Mobilization of Autologous Hematopoietic Progenitors and Subsequent Transplantation is a Safe and Feasible Procedure in Chronic Phase Chronic Myelogenous Leukemia patients presenting a Cytogenetic Resistance to Imatinib

被引：0
|
作者：
Prebet, Thomas [1 ]
Tigaud, Isabelle [2 ]
Hayette, Sandrine [2 ]
Clapisson, Gilles [3 ]
Philip, Irene [3 ]
Michallet, Mauricette [1 ]
Nicolini, Franck E. [1 ]
机构：
[1] Hop Edouard Herriot, Hematol Dept, 5 Pl Arsonval, F-69437 Lyon 03, France
[2] Ctr Hosp Lyon Sud, Lab Hematol & Cytogenet, Pierre Benite, France
[3] Ctr Leon Berard, Cellular Therapy & Hematopoiet Stem Cell Transpla, Lyon, France
来源：
HAEMATOLOGICA | 2005年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：102 / 103
页数：2
相关论文
共 50 条
  • [41] T-LYMPHOCYTES CULTURED FROM CHRONIC MYELOGENOUS LEUKEMIA BONE-MARROW SUPPRESS AUTOLOGOUS HEMATOPOIETIC PROGENITORS
    BHATIA, R
    MCGLAVE, PB
    LEUKEMIA, 1995, 9 (06) : 1006 - 1012
  • [42] IMATINIB TREATMENT IN ELDERLY PATIENTS (>65 YEARS) WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) IN EARLY CHRONIC PHASE
    Latagliata, R.
    Breccia, M.
    Carmosino, I.
    Mancini, M.
    Diverio, D.
    De Cuia, R.
    Cannella, L.
    Stefanizzi, C.
    Napoleone, L.
    Volpicelli, P.
    Vozella, F.
    Alimena, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 348 - 348
  • [43] Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation
    Cervantes, F
    Hernández-Boluda, JC
    Odriozola, J
    Camós, M
    Villalón, L
    Martínez-Climent, JA
    Del Campo, R
    García-Conde, J
    Montserrat, E
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (03) : 500 - 504
  • [44] The treatment cost to achieve a complete cytogenetic response in imatinib resistant chronic phase (CP) chronic myelogenous leukemia (CML) patients:: Nilotinib vs. dasatinib
    Mataveli, Fabio D.
    Feng, Weiwei
    Calabro, Alessandra
    Mendes, Wellington
    Hungria, Vania
    BLOOD, 2007, 110 (11) : 977A - 977A
  • [45] Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP)
    Jabbour, E.
    le Coutre, P.
    Baccarani, M.
    Bhalla, K.
    Ossenkoppele, G. J.
    Hochhaus, A.
    Gattermann, N.
    Haque, A.
    Weitzman, A.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] Imatinib Combined with Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Versus Imatinib Alone for Young Patients with Chronic Myeloid Leukemia in Chronic Phase
    Zhao, Yanmin
    Luo, Yi
    Tan, Yamin
    Shi, Jimin
    Cai, Zhen
    Lin, Maofang
    Huang, He
    BLOOD, 2014, 124 (21)
  • [47] Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation
    Millot, F
    Guilhot, J
    Nelken, B
    Leblanc, T
    De Bont, ES
    Békassy, AN
    Gadner, H
    Sufliarska, S
    Stary, J
    Gschaidmeier, H
    Guilhot, F
    Suttorp, M
    LEUKEMIA, 2006, 20 (02) : 187 - 192
  • [48] Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience
    Braziel, RM
    Launder, TM
    Druker, BJ
    Olson, SB
    Magenis, RE
    Mauro, MJ
    Sawyers, CL
    Paquette, RL
    O'Dwyer, ME
    BLOOD, 2002, 100 (02) : 435 - 441
  • [49] Cardiac risks of imatinib in chronic myelogenous leukemia (CML) patients who receive allogeneic hematopoietic cell transplantation (Allo-HCT)
    Burke, M. J.
    Gursahaney, A.
    Trotz, B.
    Luo, X.
    Baker, K. S.
    Weisdorf, D. J.
    Wagner, J. E.
    Michael, V. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP)
    Rosti, G.
    le Coutre, P.
    Bhalla, K.
    Giles, F.
    Ossenkoppele, G.
    Hochhaus, A.
    Gattermann, N.
    Haque, A.
    Weitzman, A.
    Baccarani, M.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345